Skip to content
PodParley
MPR Weekly Dose Podcast #244 — Treatment Approved for Two Rare Kidney Diseases; Elevidys Can Resume Shipments for Ambulatory Patients; Mounjaro Shows Cardio Benefits; New Wearable Cardiac Monitor Cleared; Hair Regrowth With Upadacitinib episode artwork

EPISODE · Aug 1, 2025 · 16 MIN

MPR Weekly Dose Podcast #244 — Treatment Approved for Two Rare Kidney Diseases; Elevidys Can Resume Shipments for Ambulatory Patients; Mounjaro Shows Cardio Benefits; New Wearable Cardiac Monitor Cleared; Hair Regrowth With Upadacitinib

from MPR Weekly Dose

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.

Episode metadata supplied by the publisher feed · Published Aug 1, 2025

Embed this episode

Ready to play

MPR Weekly Dose Podcast #244 — Treatment Approved for Two Rare Kidney Diseases; Elevidys Can Resume Shipments for Ambulatory Patients; Mounjaro Shows Cardio Benefits; New Wearable Cardiac Monitor Cleared; Hair Regrowth With Upadacitinib

0:00 16:09

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 16 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on August 1, 2025.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!